

DOCKET NO. 17616(AP)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of  
Old et al

Serial No: Not Assigned

Filed: Submitted herewith

For: CYCLOPENTANE  
HEPTAN(ENE)OIC ACID, 2-  
THiocarbamoyloxy AND 2-  
CARBAMOYLOXY COMPOUNDS

Group Art Unit: Not Known

Examiner: Not Known

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Respectfully submitted,

Date: 9/8/03

RJ Baran

Robert J. Baran  
Reg. No. 25,806  
ALLERGAN, INC. -T2-7H  
2525 Dupont Drive  
Irvine, CA 92612  
Tel: 714-246-4920  
Fax: 714-246-4249

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS, ON THE DATE SHOWN BELOW, BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS EXPRESS MAIL (LABEL NO. EV193718298US) IN AN ENVELOPE ADDRESSED TO: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on 9/9/03 Signature of Person Making Deposit: Jeanne Ferguson Printed Name of Person Making Deposit: BONNIE FERGUSON Date: 9/9/03

**LIST OF REFERENCES CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 17616(AP)	<b>SERIAL NO.:</b> Applied for
<b>APPLICANT:</b> Old et al	<b>TITLE:</b> CYCLOPENTANE HEPTAN(ENE) OIC ACID, 2-THiocarbamoyloxy and 2-Carbamoyloxy Compounds as Therapeutic Agents
<b>FILING DATE:</b> Submitted herewith	<b>GROUP:</b> Not assigned

**U.S. PATENT DOCUMENTS**

<b>*EXAMINER INITIAL</b>		<b>DOCUMENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB-CLASS</b>	<b>FILING DATE (if applicable)</b>
	AA	5,446,041	8/29/1995	Chan et al			
	AB	4,994,274	2/19/1991	Chan et al			
	AC	5,028,624	7/2/1991	Chan et al			
	AD	5,034,413	7/23/1991	Chan et al			
	AE						

**FOREIGN PATENT DOCUMENTS**

		<b>DOCUMENT NO.</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUB-CLASS</b>	<b>TRANSLATION (yes/no)</b>
	AH						

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, etc.)

	AT	Bito, L.Z., <u>Biological Protection with Prostaglandins</u> , "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents", Vol. 1, Chapter 18, 1985, pp. 231-252
	AU	Bito, L.Z., <u>Glaucoma, Applied Pharmacology in the Medical Treatment</u> , "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents", 1984, Chapter 20, pp. 477-505
	AV	Nilsson et al, Invest. Ophthalmol. Vis. Sci. (suppl), 284 (1987), Arvo Abstracts 9-6:00
	AW	Bito, L.Z., Arch. Ophthalmol. "Prostaglandins" "Old Concepts and New Perspectives", Vol. 105, pp. 1036-1039 (1987)
	AX	Siebold et al, Prodrug 5 3, "Esterified prostaglandin shows 'potent' promise", 1989
	AY	
	AZ	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.